These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: AGI report focuses on unanswered Norplant questions.
    Journal: Family Plan World; 1993; 3(4):29. PubMed ID: 12288087.
    Abstract:
    The Alan Guttmacher Institute, in a report by its vice president for research and its senior public policy associate, said that voluntary and universal access to Norplant may be contingent on changes in financing and cost and counseling about removal. Wyeth-Ayerst, the pharmaceutical manufacturer of Norplant, estimated a cost in 1991 of $580. Although effective for 5 years, 50% of women in clinical trials had Norplant removed after 3 years. The cost effectiveness at 3 years ($300) is still less than that of the IUD ($500), but more than that of condoms ($150). Concerns were raised about the cost in the US of $365 as a unit fee compared to the $23 offered by the Finnish manufacturer Leiras Oy Company to USAID and UNFPA for developing country use. Counseling may cost $150; the likelihood of keeping Norplant for 5 years is enhanced by adequate counseling. Side effects include spotting and increased bleeding. Another financial concern was the possibility that insurers might have changed in 5 years, and women who had insertion covered under private health insurance or Medicaid might find removal not covered. Full voluntary use is dependent on the ability o the user to have the implant removed as desired, for whatever reason, without any obstacles, perceived or otherwise.
    [Abstract] [Full Text] [Related] [New Search]